Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.
University of Tennessee, LeBonheur Children's Medical Center, Memphis 38103, USA. jdevincenzo@utmem.edu
John P
JP
DeVincenzo
Caroline B
CB
Hall
David W
DW
Kimberlin
Pablo J
PJ
Sánchez
William J
WJ
Rodriguez
Barbara A
BA
Jantausch
Lawrence
L
Corey
Jeffrey S
JS
Kahn
Janet A
JA
Englund
JoAnn A
JA
Suzich
Frances J
FJ
Palmer-Hill
Luis
L
Branco
Syd
S
Johnson
Nita K
NK
Patel
Franco M
FM
Piazza
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002460:Cell Line; D024882:Drug Resistance, Viral; D005455:Fluorescent Antibody Technique; D006760:Hospitalization; D006801:Humans; D007223:Infant; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009500:Neutralization Tests; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab